A CD40-targeting peptide, OPT501, modulates inflammation in canine diabetes mellitus improving clinical outcomes.
Saved in:
| Title: | A CD40-targeting peptide, OPT501, modulates inflammation in canine diabetes mellitus improving clinical outcomes. |
|---|---|
| Authors: | Vaitaitis GM; Department of Medicine, The University of Colorado Anschutz Medical Campus, Aurora, CO, United States., Waid DM; Op-T LLC., Aurora, CO, United States., Sharkey C; Montclair Animal Clinic, Denver, CO, United States., Sharkey S; Montclair Animal Clinic, Denver, CO, United States., Webb TL; Department of Clinical Sciences, Colorado State University, Fort Collins, CO, United States., Webb C; Department of Clinical Sciences, Colorado State University, Fort Collins, CO, United States., Wagner DH Jr; Department of Medicine, The University of Colorado Anschutz Medical Campus, Aurora, CO, United States.; Op-T LLC., Aurora, CO, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Feb 24; Vol. 17, pp. 1759373. Date of Electronic Publication: 2026 Feb 24 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1759373 |
